BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37937606)

  • 1. Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials.
    Staedtke V; Anstett K; Bedwell D; Giovannini M; Keeling K; Kesterson R; Kim Y; Korf B; Leier A; McManus ML; Sarnoff H; Vitte J; Walker JA; Plotkin SR; Wallis D
    Clin Trials; 2024 Feb; 21(1):51-66. PubMed ID: 37937606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schwannomatosis: the overlooked neurofibromatosis?
    Koontz NA; Wiens AL; Agarwal A; Hingtgen CM; Emerson RE; Mosier KM
    AJR Am J Roentgenol; 2013 Jun; 200(6):W646-53. PubMed ID: 23701098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
    Widemann BC; Acosta MT; Ammoun S; Belzberg AJ; Bernards A; Blakeley J; Bretscher A; Cichowski K; Clapp DW; Dombi E; Evans GD; Ferner R; Fernandez-Valle C; Fisher MJ; Giovannini M; Gutmann DH; Hanemann CO; Hennigan R; Huson S; Ingram D; Kissil J; Korf BR; Legius E; Packer RJ; McClatchey AI; McCormick F; North K; Pehrsson M; Plotkin SR; Ramesh V; Ratner N; Schirmer S; Sherman L; Schorry E; Stevenson D; Stewart DR; Ullrich N; Bakker AC; Morrison H
    Am J Med Genet A; 2014 Mar; 164A(3):563-78. PubMed ID: 24443315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.
    Blakeley JO; Plotkin SR
    Neuro Oncol; 2016 May; 18(5):624-38. PubMed ID: 26851632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.
    Tamura R
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis.
    Blakeley JO; Bakker A; Barker A; Clapp W; Ferner R; Fisher MJ; Giovannini M; Gutmann DH; Karajannis MA; Kissil JL; Legius E; Lloyd AC; Packer RJ; Ramesh V; Riccardi VM; Stevenson DA; Ullrich NJ; Upadhyaya M; Stemmer-Rachamimov A
    Am J Med Genet A; 2017 Jun; 173(6):1714-1721. PubMed ID: 28436162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Counseling for Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis-Practice Resource of the National Society of Genetic Counselors.
    Radtke HB; Bergner AL; Goetsch AL; McGowan C; Panzer K; Cannon A
    J Genet Couns; 2020 Oct; 29(5):692-714. PubMed ID: 32602153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
    Fisher MJ; Belzberg AJ; de Blank P; De Raedt T; Elefteriou F; Ferner RE; Giovannini M; Harris GJ; Kalamarides M; Karajannis MA; Kim A; Lázaro C; Le LQ; Li W; Listernick R; Martin S; Morrison H; Pasmant E; Ratner N; Schorry E; Ullrich NJ; Viskochil D; Weiss B; Widemann BC; Zhu Y; Bakker A; Serra E
    Am J Med Genet A; 2018 May; 176(5):1258-1269. PubMed ID: 29681099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.
    Ferner RE; Bakker A; Elgersma Y; Evans DGR; Giovannini M; Legius E; Lloyd A; Messiaen LM; Plotkin S; Reilly KM; Schindeler A; Smith MJ; Ullrich NJ; Widemann B; Sherman LS
    Am J Med Genet A; 2019 Jun; 179(6):1098-1106. PubMed ID: 30908866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What to know about schwannomatosis: a literature review.
    Schraepen C; Donkersloot P; Duyvendak W; Plazier M; Put E; Roosen G; Vanvolsem S; Wissels M; Bamps S
    Br J Neurosurg; 2022 Apr; 36(2):171-174. PubMed ID: 33263426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schwannomatosis: a Realm Reborn: year one.
    Planet M; Kalamarides M; Peyre M
    Curr Opin Oncol; 2023 Nov; 35(6):550-557. PubMed ID: 37820090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
    Louvrier C; Pasmant E; Briand-Suleau A; Cohen J; Nitschké P; Nectoux J; Orhant L; Zordan C; Goizet C; Goutagny S; Lallemand D; Vidaud M; Vidaud D; Kalamarides M; Parfait B
    Neuro Oncol; 2018 Jun; 20(7):917-929. PubMed ID: 29409008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use.
    Bettegowda C; Upadhayaya M; Evans DG; Kim A; Mathios D; Hanemann CO;
    Neurology; 2021 Aug; 97(7 Suppl 1):S91-S98. PubMed ID: 34230207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurofibromatosis- and schwannomatosis-associated tumors: Approaches to genetic testing and counseling considerations.
    Goetsch Weisman A; Weiss McQuaid S; Radtke HB; Stoll J; Brown B; Gomes A
    Am J Med Genet A; 2023 Oct; 191(10):2467-2481. PubMed ID: 37485904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New classification and approaches to the treatment of schwannomatosis.
    Makashova ES; Zolotova SV; Absalyamova OV; Galkin MV; Petrokovskaya AV; Kozlov AV; Golanov AV
    Zh Vopr Neirokhir Im N N Burdenko; 2023; 87(5):104-109. PubMed ID: 37830475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials.
    Sundby RT; Rhodes SD; Komlodi-Pasztor E; Sarnoff H; Grasso V; Upadhyaya M; Kim A; Evans DG; Blakeley JO; Hanemann CO; Bettegowda C
    Clin Trials; 2024 Feb; 21(1):40-50. PubMed ID: 37904489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives of adults with neurofibromatosis regarding the design of psychosocial trials: Results from an anonymous online survey.
    Wolters PL; Ghriwati NA; Baker M; Martin S; Berg D; Erickson G; Franklin B; Merker VL; Oberlander B; Reeve S; Rohl C; Rosser T; Vranceanu AM
    Clin Trials; 2024 Feb; 21(1):73-84. PubMed ID: 37962219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation.
    Plotkin SR; Messiaen L; Legius E; Pancza P; Avery RA; Blakeley JO; Babovic-Vuksanovic D; Ferner R; Fisher MJ; Friedman JM; Giovannini M; Gutmann DH; Hanemann CO; Kalamarides M; Kehrer-Sawatzki H; Korf BR; Mautner VF; MacCollin M; Papi L; Rauen KA; Riccardi V; Schorry E; Smith MJ; Stemmer-Rachamimov A; Stevenson DA; Ullrich NJ; Viskochil D; Wimmer K; Yohay K; ; Huson SM; Wolkenstein P; Evans DG
    Genet Med; 2022 Sep; 24(9):1967-1977. PubMed ID: 35674741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Familial schwannomatosis, a new entity distinct from neurofibromatosis type 1 and 2].
    Reinders JW; Koehler PJ
    Ned Tijdschr Geneeskd; 2007 Aug; 151(34):1891-5. PubMed ID: 17902564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis.
    Smith MJ; Kulkarni A; Rustad C; Bowers NL; Wallace AJ; Holder SE; Heiberg A; Ramsden RT; Evans DG
    Am J Med Genet A; 2012 Jan; 158A(1):215-9. PubMed ID: 22105938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.